Jaguar Health, Inc.
(NASDAQ: JAGX)

Jaguar Health
Bringing Plant-based Medicines to Life™

Overview – January 2024

Forward-Looking Statements

This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding plans by Jaguar Health, Inc. ("Jaguar" or the "Company") and Napo Therapeutics (formerly known as "Napo EU") to develop and commercialize crofelemer in Europe for HIV-related diarrhea, short bowel syndrome, congenital diarrheal disorders, and other indications, the expectation that Magdalena Biosciences will leverage Jaguar's proprietary medicinal plant library and Filament Health's proprietary drug development technology, the expectation that US$1,000,000 will be invested in Magdalena Biosciences by One Small Planet, the expectation that Magdalena Biosciences may develop a potential plant-based alternative drug for adult ADHD or other indications that is both safe and efficacious, Jaguar's plans to pursue additional business development deals, plans to expand the geography for commercialization of crofelemer, statements related to the powder formulation of crofelemer, related to NP-300, the timing of the initiation, completion, results, and publication of Phase 2 studies, Phase 3 studies, proof-of-concept studies, field studies, investigator-initiated trials, sponsored studies, and other studies, statements about possible eligibility for, and possible participation in, revenue generating early access programs, statements about the planned submission of Investigational New Drug (IND) applications to FDA, statements about plans to pursue a Priority Review Voucher (PRV), statements about the possible future market size/potential of indications, and expected milestones appearing on the list of "Upcoming Milestones", are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Please see the risk factors identified in our Annual Report on Form 10-K and our other filings with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Readers are also advised that our projected sales do not take into account the royalties and other payments we will need to make to our licensors and strategic partners. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

What We Do: Develop New Ways and Novel Plant-based Medicines to Treat Gastrointestinal Disorders

From Tree to Bottle

Crofelemer was discovered through the science of ethnobotany

Mytesi (crofelemer 125mg delayed-release tablets) is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy

Jaguar/Napo Product Portfolio – Crofelemer Pipeline in a Product

PRODUCT	INDICATIONS EVALUATED	DEVELOPMENT STAGE					GEOGRAPHIC FOCUS OF CLINICAL STUDIES
		PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	APPROVED (US)	
Mytesi (crofelemer)	Noninfectious diarrhea in adults with HIV/AIDS antiretroviral therapy						US
Crofelemer	Cancer therapy-related diarrhea (CTD)				*Phase 3 OnTarget trial ongoing globally*		Global
Powder formulation of crofelemer for oral solution	Adult short bowel syndrome (SBS) with intestinal failure		*Clinical protocol under development; Crofelemer has orphan drug designation in the EU & US*				EU & US
Crofelemer	IBS - Diarrhea Predominant (IBS-D)						US
Crofelemer	Chronic idiopathic diarrhea in non-HIV patients (investigator-initiated POC trial)						US
Powder formulation of crofelemer for oral solution	Pediatric microvillus inclusion disease (MVID), a congenital diarrheal disorder (CDD)		*Clinical protocol under development; Crofelemer has orphan drug designation in the EU & US*				US & EU
NP-300*	Symptomatic relief of diarrhea from cholera		*See footnotes below*		*US IND in effect with FDA*		US

*NP-300 and crofelemer have a similar physiological anti-secretory mechanism of action to reduce chloride ion secretion into the gut lumen and improve stool consistency. The Company has previously presented Phase 2 data on crofelemer for the treatment of devastating dehydration in cholera patients from the renowned International Centre for Diarrhoeal Disease Research (icddr,b) in Bangladesh.
*Potential opportunity for Priority Review Voucher (PRV)

Expected Near-Term Transformative Activities for Value Enhancement

- **Expected in Q1 2024:** Comprehensive results of **pivotal phase 3 OnTarget trial** of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) - **Chemotherapy-induced overactive bowel (CIOB)**
  - **A majority of subjects in this placebo-controlled two-stage trial chose to continue on to Stage II**
  - **Abstract outlining the trial design and the neglected medical need accepted by the December 2023 San Antonio Breast Cancer Symposium (SABCS)**
- Investigator-initiated proof-of-concept (POC) crofelemer studies for short bowel syndrome (SBS) with intestinal failure and microvillus inclusion disease (MVID), a rare CDD condition.
  - POC data targeted in 2024 in support of potential early patient access in specific EU countries
  - **Investigational New Drug (IND) application for crofelemer activated by FDA in August 2023 for MVID,** ultra rare disease
- **Ongoing:** Business development partnership(s) related to pipeline & global commercialization

* Key milestones are based on management estimates. Adverse events could negatively affect their business and the timeliness of achieving key milestones.

Increasing Market Value: Progression from Supportive Care to Impact on Outcome/Cost of Care to Treatment Modifying

Global market for gastrointestinal agents (Rx & OTC) projected to reach $21 billion by 2025[1]

Indication	# of Competitors	Market Size/Potential
HIV-related diarrhea	0	Jaguar estimates the U.S. market revenue potential for Mytesi® to be ~$50 million in gross annual sales
Cancer therapy-related diarrhea (CTD)	0	Projected to be 1.9 million new cancer cases in US in 2023[2] >1 million cancer patients receive chemo or radiation in a US outpatient clinic annually[3] Comparable supportive care (CINV) global market projected to reach **$3.9 billion by 2029**[4]
Short bowel syndrome (SBS) with intestinal failure / Microvillus inclusion disease (MVID), a congenital diarrheal disorder (CDD)	0	~10,000 to 20,000 people in US have SBS and approximately the same number in Europe. Orphan-drug designation supports potential accelerated approval. Estimated annual US revenue for Takeda's SBS drug Gattex: ~$555 million. Global SBS market projected to reach **$4.6 billion by 2027** with a CAGR of 26% from 2020 to 2027[5] (doesn't include potential contribution from crofelemer's novel mechanism of action)
IBS - diarrhea predominant (IBS-D)	3	~15% of adult population Most IBS products have estimated revenue potential >$1.0 billion[6]
Symptomatic relief and treatment of diarrhea from cholera and other pathogens	0	*Potential opportunity for Priority Review Voucher (PRV) PRVs are transferable, and in past transactions by other companies have sold for values ranging from $67 million to $350 million[7]

[1] Research and Markets 2017 report: "Global Gastrointestinal agents Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025"
[2] American Cancer Society. Cancer Facts & Figures 2023. Atlanta: American Cancer Society; 2023
[3] https://www.cdc.gov/cancer/preventinfections/providers.htm#print
[4] https://www.ihealthcareanalyst.com/global-chemotherapy-induced-nausea-vomiting-drugs-market/
[5] https://www.mynewsdesk.com/us/medical-technology-news/pressreleases/short-bowel-syndrome-market-global-industry-analysis-size-share-trends-revenue-forecast-2020-to-2027-3069433
[6] http://247wallst.com/healthcare-business/2015/04/27/key-analyst-sees-nearly-30-upside-in-ironwood & https://www.benzinga.com/analyst-ratings/analyst-color/17/03/9224181/analyst-synergy-pharma-could-achieve-sustainable-profita
[7] https://www.raps.org/regulatory-focus/news-articles/2017/12/regulatory-explainer-everything-you-need-to-know-about-fdas-priority-review-vouchers

Our crofelemer clinical development programs

Crofelemer is a First-in-Class Intestinal Chloride Channel Modulator

Mytesi® (crofelemer) acts at the common last step in a physiological pathway, regardless of cause, thereby normalizing defective secretion, specifically mitigating dehydration

Crofelemer does not cause constipation or alter motility



Chloride ion (Cl^-) channels in the GI tract **maintain a balance of salts—including chloride ions—and water** that allows normal stool formation

HIV or its treatment can cause damage to the GI tract, creating inflammation and a leaky gut; targeted cancer therapy and inflammatory bowel disease cause similar damage

This can further **disrupt the balance of chloride ions and water flow** into the GI lumen, leading to secretory diarrhea

Mytesi® works by regulating two chloride ion channels (CFTR and CaCC) in the GI tract, which normalizes the salt-water balance, leading to a decrease in chloride and water flow[2-4]

Acts locally in the gut via allosteric modulation of chloride channels

References: 1. Brenchley JM, Douek DC. *Mucosal Immunol.* 2008;1(1):23-30. **2.** Mytesi® [package insert]. San Francisco, CA: Napo Pharmaceuticals, Inc; 2020. **3.** Tradtrantip L, Namkung W, Verkman AS. *Mol Pharmacol*. 2010;77(1):69-78. **4.** Holodniy M, Koch J, Mistal M, et al. *Am J Gastroenterol*.1999;94(11):3267-3273.

How Crofelemer Works

- **Crofelemer is a non-opioid that works differently from other treatments for GI dysfunction**



With crofelemer, it's about waterflow

Crofelemer normalizes waterflow in the GI tract

Less water flowing into your GI tract = less watery diarrhea = greater nutrient absorption opportunity

Crofelemer acts locally in the GI tract

Opioid medicines (i.e., Imodium, loperamide) work by slowing down your GI tract, i.e., opioid constipation risk

Crofelemer is a non-opioid, non-antibiotic, non-addictive drug approved in the US for a chronic use

Cancer Therapy-related Diarrhea OnTarget PHASE 3 Trial: *Impact on Outcome*

- **Impact on outcome**
  - Roeland, et al[1]: Patients with cancer-related diarrhea (CRD) nearly 2.9 x higher cost than patients without CRD
  - Okhuysen, et al[1]: **Patients with CTD 40% more likely to discontinue chemotherapy or targeted therapy than those without CTD**

- **IIT Phase 2 data presented at December 2021 San Antonio Breast Cancer Symposium and published in *Breast Cancer Research and Treatment* in October 2022**
  - Statistical significance on collection of secondary endpoints that map to primary endpoint of Phase 3 OnTarget trial

- **Features of single Phase 3 pivotal trial, OnTarget:**
  - **Planned Label:** Prophylaxis and symptomatic relief of diarrhea in adult patients with solid tumors receiving targeted cancer therapies with or without cycle chemotherapy
  - **Primary endpoint:** Reduction in the average number of weekly loose/watery stools over a 3-month period
  - **Principal investigator (MD Anderson); US and expanding to international sites**
  - **256 patients, dbpc (double-blind, placebo-controlled)– Completed, 11% over-enrolled**

[1] Source: Okhuysen PC, et al. Abstract 12111. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.

* Key milestones are based on management estimates. Adverse events could negatively affect their business and the timeliness of achieving key milestones.

Importance of the Patient Voice in Managing Cancer Care Effectively

Paradigm shifting treatment with crofelemer

- Strength of that voice as patients continue targeted therapies for months and years rising, important, and playing a role in what type of cancer treatment fits with the goals and the life of the patient (QoL)
- Patient dignity and comfort paramount
- Cancer patients = everyday people—parents, children, at school, in the workforce

“Tolerable Toxicities” – Tolerable to Whom?

But Jaguar strives to make life a little better by taking **one pebble out of the shoe**; one side effect off the table—with preventative treatment of chemotherapy-induced overactive bowel (CIOB)

Cancer Therapy-related Diarrhea OnTarget PHASE 3 Trial: *Impact on Outcome*

- May 2023: Enrollment completed
- Comprehensive results expected in Q1 2024

OnTarget

Jaguar Health's Strategic Focus on Rare Diseases



Rare diseases, when taken together, are not that rare at all

- **30 million Americans**[1], or 10 percent of the population, have one of the approximately **7,000 known rare diseases**[2]
- An estimated **30 to 40 million people in the EU**[3] and **400 million worldwide**[4] have a rare disease
- Definition of a rare or orphan disease by region:
  - **US:** When a disease affects **<200,000** people[5]
  - **EU:** When a disease affects **<1 in 2,000** people[6]
    - **EU:** "Ultra-rare disease": When a disease affects **no more than 1 in 50,000** people[7]
- Reimbursement coverage is often available due the rare disease's high morbidity and mortality rates, and as a result of support from patient activist groups

[1 & 2] Source: https://phrma.org/Scientific-Innovation/Progress-in-Fighting-Rare-Diseases
[3] Source: Harari S. Why We Should Care About Ultra-Rare Disease. Eur Respir Rev. 2016 Jun;25(140):101-3. doi: 10.1183/16000617.0017-2016
[4] Source: https://rarediseases.org/rare-disease-day-2022-advancing-the-conversation-around-health-equity/
[5] Source: https://www.fda.gov/patients/rare-diseases-fda#
[6] Source: https://www.eurordis.org/information-support/what-is-a-rare-disease/
[7] Source: European Commission Regulation (EU) No.536/2014 of the European Parliament and of the Council of April 16, 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. 2014. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014R0536&qid=1421232837997&from=EN

Short Bowel Syndrome – Loss of Bowel with Quality-of-Life Changes

- **SBS**: Catastrophic loss of bowel often due to surgical resection of diseased or necrotic bowel (normal 15-25 feet to 5 or less feet) in adults/children (also may be congenital in children).
- **SBS with Intestinal Failure (SBS-IF)**: A condition in which your body is unable to absorb enough nutrients from the foods you eat because you do not have enough small intestine. Patients suffer from malnutrition, dehydration, imbalances of fluids and salts, excessive intestinal fluid output, and risk of organ failure.
  - Life-long parenteral nutrition (PN) may be required
  - No “standard of care” drug intervention



Parenteral nutrition backpack for patients with intestinal failure

A Global Opportunity

- SBS Patient Population:
  - ~10,000 to 20,000 in US
  - ~10,000 to 20,000 in Europe
- Despite limited treatment options, the global SBS market exceeded $568 million in 2019 and is expected to reach **$4.6 billion by 2027**[1]
  - Gattex (teduglutide):
    - Estimated share of US market: ~1-2%[3]
    - Annual cost in US: ~$485,400[4]
    - Multiple biosimilars in development by other companies
    - "**Gattex** can make abnormal cells that are already in your body grow faster. There is an increased risk that abnormal cells could become **cancer**"
  - Non-hospitalized parenteral nutrition in the US is approximately $150,000 per year[5]
  - Frequent hospitalizations for infections

[1] https://www.mynewsdesk.com/us/medical-technology-news/pressreleases/short-bowel-syndrome-market-global-industry-analysis-size-share-trends-revenue-forecast-2020-to-2027-3069433
[2] Jaguar estimate based on projected Gattex 2020 revenue of 554.9M USD (based on Takeda financial reports) divided by annual per-patient expenditure for Gattex of $376.2K in 2016 (figure sourced from https://www.ahip.org/documents/HighPriceDrugsReport.pdf)
[3] Jaguar estimate based on an estimated US SBS population of 10,000-20,000 people (www.crohnscolitisfoundation.org/sites/default/files/legacy/assets/pdfs/short-bowel-disease-crohns.pdf)
[4] 10 priciest drugs in America (https://www.benefitspro.com/2020/08/24/10-priciest-drugs-in-america/?slreturn=20221021163553)
[5] https://nutritionequity.org/wp-content/uploads/2018/05/mnea-factsheet-sbs.pdf

Current Treatment Pathway for SBS-IF Patients



Daily subcutaneous injection into abdomen, thigh, or arm; different injection site each time

Proposed Treatment Pathway: Crofelemer May Reduce Need for Parenteral Nutrition in SBS-IF Patients



Daily subcutaneous injection into abdomen, thigh, or arm; different injection site each time

Reduction of parenteral nutrition would lead to improvement of **patients' quality of life**

Microvillus Inclusion Disease (MVID): An Ultra Rare CDD

MVID is an ultra rare congenital diarrheal disorder (CDD) that affects newborns and children and leads to significant morbidity and mortality from **severe secretory diarrhea, intestinal failure**

Key Milestones:

- **Investigational New Drug (IND) application for crofelemer for MVID activated by FDA** in August 2023
- Single digit number of patients treated to receive approval?

* Adverse events could negatively affect the timeliness of submitting the Investigational New Drug (IND) application. There is a probability that the FDA may not approve Company's IND application.

Napo Therapeutics: Exclusive Licensee of Jaguar's Crofelemer Drug Product for Europe

> 90% owned by Jaguar

- **Napo Therapeutics' Mission:** Rare disease business model
- ***Initial orphan target indications:*** Short bowel syndrome (SBS) with intestinal failure, and microvillus inclusion disease (MVID), a congenital diarrheal disorder (CDD)
  - Pursuing accelerated conditional marketing authorization from the European Medicines Agency (EMA) under orphan drug designation
  - In 2023 Jaguar & Napo Therapeutics supporting six investigator-initiated proof-of-concept (POC) studies of crofelemer in patients with SBS and CDD
  - Publication of POC data from these trials could support early patient access to crofelemer for SBS or CDD in specific EU countries
  - Early access programs, which do not exist in the US, are revenue generating, and reimbursable for participating patients

napo therapeutics

* There is a probability that accelerated conditional marketing authorization may not be granted, which may negatively impact Company's business operations and projected revenue

NP-300 Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera and Other Pathogens

Cholera is designated as a rare disease in the United States, where nearly all reported cases are acquired during international travel

Our NP-300 Drug Candidate:

- Second-generation anti-secretory drug
- Same source plant as crofelemer

- Clinical proof-of-concept for the CFTR ion channel MOA of NP-300 demonstrated by crofelemer for the reduction of diarrhea-associated dehydration in cholera patients: International Centre for Diarrhoeal Disease Research (icddr,b) in Bangladesh
- IND activated
- Plan to pursue Priority Review Voucher (PRV) (in past transactions by other companies PRVs have sold for values ranging from $67M - $350M)

Canalevia®-CA1 (Crofelemer): A New Standard of Care For Treatment of Chemotherapy-induced Diarrhea (CID) in Dogs Launched April 2022

Canalevia-CA1 received conditional approval in December 2021—the first and only product indicated for CID in dogs to receive any type of approval from FDA

Canalevia®-CA1
(crofelemer delayed-release tablets)

Approximately 1 in 4 dogs will, at some stage in their life, develop neoplasia. Almost half of dogs over the age of 10 will develop cancer. ~6 million new cancer diagnoses are made in dogs each year in the U.S.

Pet owners' willingness to pay for life saving treatments and procedures increases with patient comfort.

For the most part, dogs receive human chemotherapeutic agents during treatment and suffer the same side effects as humans, which means ~40% of treated dogs may have their chemotherapy reduced, changed, or discontinued due to diarrhea—which can compromise the full benefit of the chemotherapy agent.

Similar dynamics to human specialty market, but with greater correlation between gross and net revenue with pet owner paying out of pocket.

Conditional approval in dogs is similar to orphan drug designation in humans.

Jaguar Animal Health

https://www.avma.org/resources/pet-owners/petcare/cancer-pets

Net Revenue


$3,500,000
$3,000,000
$2,500,000
$2,000,000
$1,500,000
$1,000,000
$500,000
$0
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Net Revenue ($)

Jaguar and Filament Health, with Funding from One Small Planet, Form Joint Venture *Magdalena Biosciences* to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses

Magdalena currently valued at US$5.0 million based on initial funding of US$1.0 million from One Small Planet

- Magdalena Biosciences leverages Jaguar's proprietary 2300 medicinal plant library
- Jaguar owns ~40% of Magdalena
- **Goal of Collaboration:** To extend the botanical drug development capabilities of Jaguar to:
  - Develop pharmaceutical-grade, standardized drug candidates for mental health disorders **including attention-deficit/hyperactivity disorder (ADHD) in adults**
  - **Partner with a potential future licensee** to develop and commercialize these novel plant-based drugs

Jaguar Health
Bringing Plant-based Medicines to Life™

Filament Health

ONE SMALL PLANET

Magdalena Biosciences

Program to support the discovery and development of **novel psychoactive medicines derived from plants** for mental health and CNS disorders

- Leverage Company's proprietary library of ~2,300 plants and ~3,500 plant extracts with ethnomedicinal investigation
- Seeking next generation first-in-class agents, novel mechanisms of action, disease modifying agents

Picralima nitida plant, the source of the active ingredient alstonine

Eight key agents being pursued by psychedelic-focused companies:

- LSD and derivatives
- Psilocybin and derivatives (mushrooms in the genus *Psilocybe)*
- Iboga and derivatives
- Toad sections from *Bufus Alvarius* 5-MeO-DMT
- MDMA (referred to as ecstasy or Molly)
- Ketamine
- Mescaline and derivatives (peyote is most well-known source but not only source)
- DMT and derivatives (most well-known source is the *Banisteriopisis* and *Psychotria viridis* mixture known as Ayahuasca)

Peyote (*Lophophora williamsii*), a source of mescaline

Key Milestones

- **Q4 2023:** Publication of canine chemotherapy study
- **Q1 2024:** Comprehensive results of pivotal phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea (CTD) expected
- **Q1 2024**: Additional rare disease initiatives, real world PRO
- **Q2 2024**: Targeting: ASCO publication/presentation of OnTarget results
- **2024:** Investigator-initiated proof-of-concept (POC) studies of crofelemer for SBS and CDD
- **2024:** Publication of POC data for SBS and CDD, supporting the potential for expanded patient access through early access programs in specific EU countries for these diseases
- **2024-2025:** Participation in revenue generating early access programs in EU for crofelemer for SBS and CDD
- **Ongoing:** Business development partnership(s) related to pipeline & global commercialization



* Key milestones are based on management estimates. Adverse events could negatively affect Company's business and the timeliness of achieving key milestones.

Jaguar/Napo Pharmaceuticals Executive Management Team

Name / Title	Experience
Lisa Conte Founder & CEO	• 30+ years of industry experience • Obtained first anti-secretory human product FDA approval • Board of Directors of Healing Forest Conservancy • Raised over $400 mm
Carol Lizak, MBA Chief Financial Officer	• 20 years corporate controllership and financial planning and analysis experience under U.S. GAAP & IFRS • 10+ years with public companies including foreign subs (5 years in biopharma)
Steven King, PhD Chief Sustainable Supply, Ethnobotanical Research & IP Officer	• Served as head of sustainable supply, ethnobotanical research & IP: 1989-2020 • Board of Directors of Healing Forest Conservancy
Pravin Chaturvedi, PhD Chief Scientific Officer Chair of Scientific Advisory Board	• 25+ years drug development experience • Co-Founded Scion, IndUS and Oceanyx Pharmaceuticals • Successfully developed Mytesi® (first pivotal adaptive design) and 7 pharmaceutical products
Karen J. Brunke, PhD Executive VP, Corporate & Business Development	• 30+ years experience in research, operations and BD in pharma/biotech • Primary responsibility in deals with MedImmune, Astellas; closed GSK deal • Successfully developed GMOs at Sandoz while Research Director
Darlene Horton, M.D. Chief Medical Officer	• Biopharmaceutical veteran and leading clinical development expert • 25 years experience in development of investigational and commercialized biopharmaceutical and drug-device combination products; experienced in design of SBS clinical programs
David Sesin, PhD Chief Manufacturing Officer	• Pharmaceutical scientist with experience from drug discovery through manufacturing • Developed crofelemer manufacturing process
Jonathan Wolin, JD, MBA Chief of Staff, Chief Compliance Officer & General Counsel	• Extensive experience providing legal advice and guidance to public and private companies in the healthcare and biotechnology industries
Ian H. Wendt, MBA Chief Commercial Officer	• Has held commercial leadership roles across sales, marketing and operations at some of the largest brands in the pharmaceutical industry over past 25 years
Allison A. Shrier, M.D. Napo Pharmaceuticals VP, Clinical Research & Medical Affairs	• Physician-scientist-entrepreneur with expertise in oncology & metabolism • Expertise in end-to-end drug discovery & development including population identification, target product profiles development, hit design, selection & optimization, preclinical & clinical study planning

Napo Therapeutics Scientific Advisors

Name / Title	Experience
Mohammed Miqdady, MD	• Division Chief of the Pediatric Gastroenterology, Hepatology & Nutrition Division at Sheikh Khalifa Medical City in the United Arab Emirates. American Board certified in Pediatric Gastroenterology, Hepatology and Nutrition. Also serves as an Adjunct Staff at the Cleveland Clinic in Ohio, U.S.
Loris Pironi, MD	• Full Professor of Food and Dietetic Sciences (Clinical Nutrition), School of Medicine, Department of Medical and Surgical Science, University of Bologna. Chairman of the Home Artificial Nutrition & Chronic Intestinal Failure Working Group of the European Society for Clinical Nutrition and Metabolism (ESPEN). Chairman of the Scientific Committee of the Italian Society for Artificial Nutrition and Metabolism (SINPE).
Antonino Morabito, MD	• Professor of Pediatric Surgery University of Florence and Chief of Surgery at the Meyer Children's Hospital. Consultant Intestinal Failure Surgeon, Salford Royal Foundation Trust-University of Salford.
Francisca Joly, MD	• University Professor – Hospital Practitioner, Department of Gastroenterology, MICI and Nutritional Assistance, Beaujon Hospital, Paris. President of the SFNCM Francophone Clinical Nutrition and Metabolism Society. Associate manager of MaRDi center (Rare Digestive Diseases) for adults (coordination: Necker-Enfants Malade Hospital & Robert Debré Hospital)
Simon Gabe, MD MSc BSc MBBS FRCP	• Consultant Gastroenterologist at St Mark's Hospital in Harrow. He co-chairs the supra-regionally funded Intestinal Rehabilitation service, one of two centers in the UK funded to provide this service. He was appointed as Senior Lecturer at St Mark's and Imperial College in 2000.

napo therapeutics

Investment Highlights

Mytesi (Crofelemer): FDA-Approved Human Drug	• Only FDA-approved diarrhea treatment that's been studied specifically in adults with HIV / AIDS • Supply chain in place
Planned Crofelemer Expansion	**Progression from supportive care to impact on outcome/cost of care to treatment modifying** • Napo's CTD - Phase 3 OnTarget study, comprehensive results expected Q1 2024 • SBS with intestinal failure - treatment modifying • 3 IITs (functional diarrhea, IBS, IBD)
Strategic Focus on Rare Diseases	• SBS with intestinal failure • Initial CDD target indication: microvillus inclusion disease (MVID) • Other rare diseases, real world PRO
Canalevia-CA1 for chemotherapy-induced diarrhea (CID) in dogs	• Canalevia-CA1 FDA conditionally approved December 2021 • Estimated 6 million new cancer diagnoses in dogs each year in US; 25-40% experience diarrhea • Management of CID in dogs is a comfort issue for dogs and may also help dogs better tolerate chemo and improve the home/living environment for owners
Strategic Partnerships	• Unencumbered global commercial rights to Mytesi/crofelemer pipeline • License deals completed in Europe, Canada, Middle East; ongoing discussions for Asia, LATAM • Magdalena Biosciences leveraging proprietary 2,300-plant ethnobotanical database
Strong Management Team	• Key management has been with the team for >20 years • Chairman of board and key investors have invested for >30 years
Proprietary Position	• ~148 patents (majority do not expire until 2027 - 2031) and ~50 patents pending • Sustainable supply of commercial scale of raw material sourcing • Botanical guidance protection – no practical generic pathway

Jaguar Health

Bringing Plant-based Medicines to Life™

Jaguar Health, Inc. (NASDAQ: JAGX)

Contact:
hello@jaguar.health